Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
6/2 15:00
Late last month, Bristol Myers Squibb's (NYSE: BMY) immunology drug, Sotyktu, received good news. The medicine was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adult patients with moderate to severe plaque pso...